Related Experiment Video
Updated: Feb 25, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts
Jared A Wallace1, Ryan M O'Connell1
1Department of Pathology, University of Utah, Salt Lake City, UT.
Abstract:
Acute myeloid leukemia (AML) is a deadly hematologic malignancy characterized by the uncontrolled growth of immature myeloid cells. Over the past several decades, we have learned a tremendous amount regarding the genetic aberrations that govern disease development in AML. Among these are genes that encode noncoding RNAs, including the microRNA (miRNA) family. miRNAs are evolutionarily conserved small noncoding RNAs that display important physiological effects through their posttranscriptional regulation of messenger RNA targets. Over the past decade, studies have identified miRNAs as playing a role in nearly all aspects of AML disease development, including cellular proliferation, survival, and differentiation. These observations have led to the study of miRNAs as biomarkers of disease, and efforts to therapeutically manipulate miRNAs to improve disease outcome in AML are ongoing. Although much has been learned regarding the importance of miRNAs in AML disease initiation and progression, there are many unanswered questions and emerging facets of miRNA biology that add complexity to their roles in AML. Moving forward, answers to these questions will provide a greater level of understanding of miRNA biology and critical insights into the many translational applications for these small regulatory RNAs in AML.
Insights
MicroRNAs (miRNAs) are key regulators in acute myeloid leukemia (AML) development, influencing cell growth and survival. Ongoing research explores their potential as biomarkers and therapeutic targets for AML.
Area of Science:
- Hematologic Malignancies
- Molecular Biology
- Cancer Genetics
Background:
- Acute myeloid leukemia (AML) is a severe blood cancer driven by genetic mutations.
- Noncoding RNAs, particularly microRNAs (miRNAs), are increasingly recognized for their roles in cancer.
- miRNAs regulate gene expression post-transcriptionally, impacting cellular processes.
Purpose of the Study:
- To review the established and emerging roles of miRNAs in AML pathogenesis.
- To highlight the potential of miRNAs as diagnostic biomarkers and therapeutic targets in AML.
- To identify key unanswered questions in miRNA biology relevant to AML.
Main Methods:
- Literature review of studies on miRNA function in AML.
- Analysis of genetic aberrations and their impact on miRNA expression in AML.
- Examination of miRNA-mediated post-transcriptional regulation in myeloid cells.
Main Results:
- miRNAs are implicated in critical AML processes: proliferation, survival, and differentiation.
- miRNAs have shown promise as biomarkers for AML diagnosis and prognosis.
- Therapeutic strategies targeting miRNAs are under investigation for AML treatment.
Conclusions:
- miRNAs play a multifaceted role in AML initiation and progression.
- Further research into miRNA biology is crucial for understanding AML and developing novel therapies.
- Translational applications of miRNAs in AML are a significant area of ongoing investigation.
More Related Videos
09:06MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
